|
US5138036A
(en)
*
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
|
EP0642530B1
(de)
*
|
1992-05-20 |
1998-08-12 |
BASF Aktiengesellschaft |
Derivate des Dolastatin
|
|
US5831002A
(en)
*
|
1992-05-20 |
1998-11-03 |
Basf Aktiengesellschaft |
Antitumor peptides
|
|
PL178766B1
(pl)
*
|
1992-12-16 |
2000-06-30 |
Basf Ag |
Nowe peptydy
|
|
US5410024A
(en)
*
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
|
DE4415998A1
(de)
*
|
1994-05-06 |
1995-11-09 |
Basf Ag |
Neue Tetrapeptide, ihre Herstellung Verwendung
|
|
US5807984A
(en)
*
|
1995-11-09 |
1998-09-15 |
Basf Aktienegesellschaft |
Oligopeptides, the preparation and use thereof
|
|
US20010009901A1
(en)
|
1996-12-11 |
2001-07-26 |
Basf Aktiengesellschaft Germany |
Antineoplastic peptides
|
|
US5939527A
(en)
*
|
1996-07-30 |
1999-08-17 |
Basf Aktiengesellschaft |
Tetrapeptides as antitumor agents
|
|
US5741892A
(en)
*
|
1996-07-30 |
1998-04-21 |
Basf Aktiengesellschaft |
Pentapeptides as antitumor agents
|
|
US5965537A
(en)
*
|
1997-03-10 |
1999-10-12 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
|
|
US6103698A
(en)
*
|
1997-03-13 |
2000-08-15 |
Basf Aktiengesellschaft |
Dolastatin-15 derivatives in combination with taxanes
|
|
US6143721A
(en)
|
1997-07-18 |
2000-11-07 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives
|
|
US6015790A
(en)
*
|
1997-10-06 |
2000-01-18 |
Basf Aktiengesellschaft |
Methods and compositions for treating rheumatoid arthritis
|
|
US5985837A
(en)
*
|
1998-07-08 |
1999-11-16 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6884869B2
(en)
*
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
DK1545613T3
(da)
*
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
AU2005322410B2
(en)
|
2004-11-30 |
2011-11-10 |
Amgen Fremont Inc. |
Antibodies directed to GPNMB and uses thereof
|
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
|
EP1883627B1
(de)
|
2005-05-18 |
2018-04-18 |
Pharmascience Inc. |
An die bir-domäne bindende verbindungen
|
|
DK1912671T3
(da)
|
2005-07-18 |
2017-11-27 |
Seattle Genetics Inc |
Beta-glucuronid-linker-lægemiddelkonjugater
|
|
WO2007131366A1
(en)
|
2006-05-16 |
2007-11-22 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
JP5496897B2
(ja)
|
2007-10-04 |
2014-05-21 |
ザイモジェネティクス， インコーポレイテッド |
Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
|
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
ES2458541T5
(en)
|
2008-05-02 |
2025-08-04 |
Seagen Inc |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
CA2774032C
(en)
|
2009-10-23 |
2019-03-26 |
Millennium Pharmaceuticals, Inc. |
Anti-gcc antibody molecules and related compositions and methods
|
|
SI2510011T1
(sl)
|
2009-12-09 |
2014-12-31 |
Institut National De La Sante Et De La Recherche Medicale |
Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
|
|
AU2011213609B2
(en)
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
SG182724A1
(en)
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
PT3178851T
(pt)
|
2010-03-31 |
2020-07-17 |
Boehringer Ingelheim Int |
Anticorpos anti-cd40
|
|
MX347954B
(es)
|
2010-09-29 |
2017-05-19 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
|
CA2815363C
(en)
|
2010-10-22 |
2020-07-14 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
JP6215194B2
(ja)
|
2011-05-16 |
2017-10-18 |
コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． |
生体直交型薬物活性化
|
|
EP2710040B1
(de)
|
2011-05-19 |
2017-07-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-her3-antikörper und deren verwendungen
|
|
EP3228325A1
(de)
|
2011-06-10 |
2017-10-11 |
Mersana Therapeutics, Inc. |
Protein-polymer-wirkstoffkonjugate
|
|
JP6033293B2
(ja)
|
2011-06-22 |
2016-11-30 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） |
抗Ａｘｌ抗体及びその使用
|
|
WO2012175692A1
(en)
|
2011-06-22 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
|
EA201490974A1
(ru)
|
2011-11-16 |
2014-09-30 |
Эмджен Инк. |
СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
|
SG11201408494UA
(en)
|
2012-06-19 |
2015-02-27 |
Ambrx Inc |
Anti-cd70 antibody drug conjugates
|
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
|
WO2014081303A1
(en)
|
2012-11-22 |
2014-05-30 |
Tagworks Pharmaceuticals B.V. |
Chemically cleavable group
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
EP2931316B1
(de)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxylpolymer-heilmittelproteinkonjugate
|
|
KR102305226B1
(ko)
|
2013-03-15 |
2021-09-29 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
항-egfr 항체 약물 접합체 제형
|
|
HK1219056A1
(zh)
|
2013-03-15 |
2017-03-24 |
艾伯维公司 |
抗体药物偶联物(adc)纯化
|
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
CA2925393C
(en)
|
2013-10-11 |
2023-03-07 |
Dimiter Dimitrov |
Tem8 antibodies and their use
|
|
KR102572149B1
(ko)
|
2013-10-11 |
2023-08-30 |
아사나 바이오사이언시스 엘엘씨 |
단백질-폴리머-약물 접합체
|
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
CA2926586C
(en)
|
2013-10-11 |
2020-04-07 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2015057461A2
(en)
|
2013-10-18 |
2015-04-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
BR112016010336A2
(pt)
|
2013-11-07 |
2017-10-03 |
Inst Nat Sante Rech Med |
Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
EP3659624B1
(de)
|
2014-01-15 |
2022-11-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Auf knorpel gerichtete wirkstoffe und deren verwendung
|
|
CN106414465B
(zh)
|
2014-02-28 |
2021-11-16 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
|
TWI731535B
(zh)
|
2014-03-21 |
2021-06-21 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
ES2848857T3
(es)
|
2014-07-31 |
2021-08-12 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
WO2016130969A1
(en)
|
2015-02-13 |
2016-08-18 |
George Robert Pettit |
Silstatin compounds
|
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
|
ES2884844T3
(es)
|
2015-03-09 |
2021-12-13 |
Agensys Inc |
Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
|
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
|
US10591465B2
(en)
|
2015-05-12 |
2020-03-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
|
|
EP3298044B1
(de)
|
2015-05-22 |
2021-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Menschliche monoklonale antikörperfragmente zur hemmung sowohl der katalytischen cath-d-aktivität und als auch deren bindung an den lrp1-rezeptor
|
|
EP3303391A1
(de)
|
2015-05-26 |
2018-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen (ntsr1-inhibitoren) zur behandlung von hepatozellulären karzinomen
|
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
|
WO2015151078A2
(en)
|
2015-06-15 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Hydrophilic linkers for conjugation
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
WO2017062820A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
EP3419655A1
(de)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptidimpfstoffe mit selbstanordnenden polymernanopartikeln
|
|
WO2017151425A1
(en)
|
2016-02-29 |
2017-09-08 |
Madrigal Pharmaceuticals, Inc. |
Hsp90 inhibitor drug conjugates
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
MA43835A
(fr)
|
2016-03-25 |
2018-11-28 |
Seattle Genetics Inc |
Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
|
|
BR112018075644A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de anticorpo e fármaco
|
|
AU2017277914A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
|
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
|
RS61828B1
(sr)
|
2016-06-08 |
2021-06-30 |
Abbvie Inc |
Anti-b7-h3 antitela i antitelske konjugacije lekova
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
JP7350313B2
(ja)
|
2016-12-16 |
2023-09-26 |
ブルーフィン バイオメディシン， インコーポレイテッド |
抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
|
|
EP3882265B1
(de)
|
2017-01-09 |
2022-11-02 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-mesothelin-immuntherapie
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
|
EP3612567B1
(de)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
|
|
JP7657440B2
(ja)
|
2017-06-12 |
2025-04-07 |
ブルーフィン バイオメディシン， インコーポレイテッド |
抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
|
|
CA3066754A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
|
EP3658588A1
(de)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
|
|
WO2019028051A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
KR20200051802A
(ko)
|
2017-09-18 |
2020-05-13 |
서트로 바이오파마, 인크. |
항-엽산 수용체 알파 항체 접합체 및 이의 용도
|
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
|
|
CN117756946A
(zh)
|
2017-11-03 |
2024-03-26 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
US11629167B2
(en)
|
2017-11-09 |
2023-04-18 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Betulastatin compounds
|
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
|
ES2975330T3
(es)
|
2018-05-04 |
2024-07-04 |
Tagworks Pharmaceuticals B V |
Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
|
|
US20210299286A1
(en)
|
2018-05-04 |
2021-09-30 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
JP7504808B2
(ja)
|
2018-06-29 |
2024-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
自己免疫疾患の処置における使用のための抗ｃｄ４０抗体
|
|
EP3820909B1
(de)
|
2018-07-11 |
2023-03-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoklonaler antikörper zum nachweis des antiviralen arzneimittels emtricitabin (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidin)
|
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
|
JP7546553B2
(ja)
|
2018-09-20 |
2024-09-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
|
|
CN113286607B
(zh)
|
2018-09-26 |
2024-07-12 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
|
AU2019387377A1
(en)
|
2018-11-30 |
2021-06-17 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
US11969443B2
(en)
|
2019-03-06 |
2024-04-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
|
CN114364801B
(zh)
|
2019-05-30 |
2024-04-19 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
IL289093B2
(en)
|
2019-06-17 |
2025-02-01 |
Tagworks Pharmaceuticals B V |
Compounds for a fast and efficient "click release" reaction
|
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
|
TWI877278B
(zh)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
|
JP2023542678A
(ja)
|
2020-09-21 |
2023-10-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
炎症状態の処置のための抗ｃｄ４０抗体の使用。
|
|
CN116801898A
(zh)
|
2020-11-05 |
2023-09-22 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
MX2023009497A
(es)
|
2021-02-15 |
2023-08-23 |
Takeda Pharmaceuticals Co |
Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
|
|
CN117396231A
(zh)
|
2021-04-30 |
2024-01-12 |
新基公司 |
使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
|
|
AU2022304582A1
(en)
|
2021-06-29 |
2024-02-01 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
|
CN118339280A
(zh)
|
2021-09-06 |
2024-07-12 |
维拉克萨生物技术有限责任公司 |
用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
DK4186529T3
(da)
|
2021-11-25 |
2025-08-25 |
Veraxa Biotech Gmbh |
Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
|
|
KR20240105469A
(ko)
|
2021-11-25 |
2024-07-05 |
베락사 바이오테크 게엠베하 |
유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
|
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
|
DK4314031T3
(da)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
Maskeret il12-protein
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
EP4547284A1
(de)
|
2022-06-30 |
2025-05-07 |
Sutro Biopharma, Inc. |
Anti-ror1-antikörper und antikörperkonjugate, zusammensetzungen mit anti-ror1-antikörpern oder antikörperkonjugaten sowie verfahren zur herstellung und verwendung von anti-ror1-antikörpern und antikörperkonjugaten
|
|
CA3261603A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
ANTIBODY-DRUG CONJUGATES
|
|
AU2023314413A1
(en)
|
2022-07-28 |
2025-02-13 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
KR20250169530A
(ko)
|
2023-03-10 |
2025-12-03 |
태그웍스 파마슈티컬스 비.브이. |
개선된 t-링커를 갖는 트랜스-사이클로옥텐
|
|
AR132178A1
(es)
|
2023-03-22 |
2025-06-04 |
Salubris Biotherapeutics Inc |
Dominios de unión al antígeno anti-5t4, conjugados anticuerpo-fármaco, y métodos de uso de los mismos
|
|
CN121511261A
(zh)
|
2023-05-17 |
2026-02-10 |
国家健康与医学研究院 |
抗组织蛋白酶-d抗体
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
CN121646574A
(zh)
|
2023-07-27 |
2026-03-10 |
维拉克萨生物技术有限责任公司 |
亲水性反式环辛烯(hyTCO)化合物、含有该化合物的构建体和缀合物
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2025078841A2
(en)
|
2023-10-11 |
2025-04-17 |
Antikor Biopharma Limited |
Antibodies, conjugates, and uses thereof
|
|
US12540197B2
(en)
|
2023-10-13 |
2026-02-03 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025174248A1
(en)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctenes with "or gate" release
|
|
WO2025223455A1
(en)
|
2024-04-24 |
2025-10-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-ptk7/b7h3 antibodies and uses thereof
|
|
WO2025250825A1
(en)
|
2024-05-30 |
2025-12-04 |
Sutro Biopharma, Inc. |
Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
|
|
WO2025248500A1
(en)
|
2024-05-31 |
2025-12-04 |
Janssen Biotech, Inc. |
Antibody drug conjugates that target enpp3
|
|
US20260000765A1
(en)
|
2024-06-27 |
2026-01-01 |
Lentigen Technology, Inc. |
CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
|
|
WO2026043823A2
(en)
|
2024-08-19 |
2026-02-26 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
|
|
WO2026043376A1
(en)
|
2024-08-22 |
2026-02-26 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctene formulations
|